They reflect a rapid and substantial shift in the biological and clinical spectrum of prostate cancer, as we now define, diagnose, register and treat it, following the introduction of sensitive new diagnostic techniques such as the PSA test. This evidence concerns the gene KLK3 and prostate cancer.